• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    November 17, 2023 - FDA Roundup: November 17, 2023

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMY alert in real time by email
    For Immediate Release:
    November 17, 2023

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation, which facilitated the Operational Evaluation of FDA’s Human Foods Program and the subsequent evaluation and report submitted to FDA Commissioner Robert Califf on December 6, 2022. In the interview, Winckler discusses what prompted the establishment of the foreign offices, and how this experience influenced her work on Reagan-Udall’s evaluation of the FDA’s human foods program.
    • On Thursday, the FDA announced two new initiatives to help ensure pulse oximetry is equitable and accurate for all patients. To that end, the FDA published a new discussion paper for public comment outlining one possible approach to improve the quality of premarket studies and associated methods used to evaluate the performance of pulse oximeters, taking into consideration patient skin pigmentation and patient-reported race and ethnicity. The agency also announced an upcoming advisory committee on Feb. 2, 2024, where pulse oximeters will be discussed.    
    • On Thursday, the FDA approved enzalutamide (Xtandi, Astellas Pharma US, Inc.) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). View full prescribing information for Xtandi.
    • On Thursday, the FDA approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. FDA also approved the FoundationOne® CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with capivasertib with fulvestrant. View full prescribing information for Truqap.
    • On Thursday, the FDA posted an update on the investigation of elevated lead levels in cinnamon applesauce pouches. The FDA, along with CDC and state and local partners, continues investigating reports of elevated blood lead levels in individuals with reported exposure to Apple Cinnamon Fruit Puree pouches manufactured in Ecuador and sold under WanaBana, Weis, and Schnucks brands. As of November 16, 2023, there have been 34 reports of illness potentially linked to recalled product submitted to the FDA. The FDA is continuing to evaluate incoming adverse reports of illnesses. The FDA’s leading hypothesis is that cinnamon used in these recalled pouches is the likely source of contamination for these products; however, the FDA has not yet been able to collect and test samples of the cinnamon used in the recalled products. The FDA is continuing to work with Ecuadorian authorities to investigate the source of the cinnamon. At this time, FDA has no indication that this issue extends beyond these recalled products, but to further protect public health, the FDA is screening incoming shipments of cinnamon from multiple countries for lead contamination. Additional information is available in the FDA Advisory.
    • On Thursday, the Centers for Disease Control and Prevention announced the release of more than 77,000 additional doses of Beyfortus (nirsevimab-alip), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease. These additional doses will be distributed immediately to physicians and hospitals through the Vaccines for Children Program and commercial channels – improving the availability for parents seeking to protect their eligible children, particularly those at highest risk of severe illness. CDC and FDA will continue to be in close contact with manufacturers to help ensure the availability of additional doses through end of this year and for early 2024 to meet the demand.
    • On Thursday, the FDA approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. View the full prescribing information for Keytruda.
    • On Thursday, the FDA approved repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This is the first FDA approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1 tyrosine kinase inhibitor (TKI), in addition to patients who are TKI naïve. View full prescribing information for Augtyro.
    • On Thursday, the FDA issued warning letters to seven online retailers for selling and/or distributing unauthorized e-cigarettes. The unauthorized e-cigarettes are packaged to look like youth-appealing toys and drink containers, including milk cartons, soft drink bottles, and slushies. The products’ design may also help youth conceal the e-cigarettes from adults or be confused with an everyday object and the contents accidently ingested by young children.
    • On Thursday, the FDA issued the final guidance: Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act (“506J Guidance”). The FDA is issuing this guidance to address section 506J of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as it relates to notifying the FDA of a permanent discontinuance or interruption in the manufacturing of certain devices likely to lead to a meaningful disruption in the domestic supply of that device during, or in advance of, a public health emergency (PHE).
    • On Thursday, the FDA issued the draft guidance: Select Updates for the 506J Guidance: 506J Device List and Additional Notifications. This draft guidance provides information to facilitate voluntary notifications on supply chain issues at any time, unrelated to the declaration or potential declaration of a PHE. The Select Update also includes a list of devices, by FDA product code, for which a manufacturer of such devices is required to notify the FDA in accordance with section 506J (“506J Device List”). The FDA intends to incorporate the updates proposed in this draft guidance into the 506J Guidance as one final guidance document after obtaining and considering public comment on these proposed select updates.

    For more information, visit the 506J Device List webpage. 

    • On Thursday, the FDA issued this final guidance: Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions. Medical device manufacturers are using computational modeling and simulation (CM&S), also called in silico methods, increasingly to help streamline device development and premarket evaluation. This final guidance: 
      • Provides a framework that manufacturers can use to show that computational models used to support regulatory submissions are credible. 
      • Intended to help improve the consistency and transparency of FDA reviews of regulatory submissions that include CM&S methods.
      • Applies to CM&S models that are physics-based or mechanistic. It does not apply to standalone machine learning or artificial intelligence-based models.
      • Provides a framework for demonstrating CM&S credibility through key concepts from the the FDA-recognized standard American Society of Mechanical Engineers (ASME) V&V 40-2018 Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices.

    On January 11, 2024, the FDA will host a webinar for industry and others interested in learning more about the guidance.

    • On Wednesday, the FDA approved Defencath, a catheter lock solution (CLS) indicated to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). Defencath is indicated for use in a limited and specific population of patients. Defencath is intended for use as a catheter lock solution only and is not meant to be injected into the body or used as a catheter lock flush product. Each Defencath single-dose vial is designed for use with a single patient as a single instillation in the CVC. Defencath is the third drug to receive approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) and is manufactured by CorMedix, Inc.  
    • On Wednesday, the FDA announced a new MITRE report, Next Steps Toward Managing Legacy Medical Device Cybersecurity Risks. The FDA acknowledges that legacy medical devices—those that cannot be reasonably protected against current cybersecurity threats—can pose significant risks to the health care sector. Legacy devices were legally put on the market and may still be broadly in use. To address this important security issue, the FDA contracted with MITRE to develop the report that outlines practical approaches and recommendations that can further drive sector-wide legacy device cyber risk management efforts.
    • On Tuesday, the FDA updated the webpage Advancing Alternatives Methods at FDA with new information and a revised format to provide better access to more in-depth content on the FDA’s continuing work to advance new alternative methods for regulatory use. The FDA has a long-standing commitment to the development and use of new technologies that have the potential to provide more timely and more predictive information to assess certain aspects of the FDA-regulated products while also replacing, reducing, and/or refining animal testing. The new webpage will continue to provide updates on this and more of our work to advance alternative methods.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

     
    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY
    $CRMD

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    CorMedix Inc.
    $CRMD
    3/7/2025$18.00Outperform
    Leerink Partners
    CorMedix Inc.
    $CRMD
    1/13/2025$15.00Buy
    D. Boral Capital
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Bristol-Myers Squibb Company
    $BMY
    12/10/2024$63.00Neutral
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    11/15/2024Peer Perform
    Wolfe Research
    Bristol-Myers Squibb Company
    $BMY
    11/13/2024Neutral → Outperform
    Daiwa Securities
    More analyst ratings

    $BMY
    $CRMD
    Financials

    Live finance-specific insights

    See more
    • CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys

      5/6/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

      BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link   About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr

      4/29/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

      SC 13G/A - CorMedix Inc. (0001410098) (Subject)

      11/14/24 4:34:05 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

      SC 13G/A - CorMedix Inc. (0001410098) (Subject)

      2/14/24 10:37:21 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CorMedix Inc.

      SC 13G - CorMedix Inc. (0001410098) (Subject)

      2/13/24 5:02:29 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Chief Commercial Officer Lenkowsky Adam

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      5/5/25 5:41:48 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Glob. Prod. Dev. & Supply Shanahan Karin converted options into 3,306 shares and covered exercise/tax liability with 1,692 shares, increasing direct ownership by 13% to 13,797 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/3/25 5:15:32 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BMY
    $CRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys

      5/6/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

      BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link   About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr

      4/29/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $BMY
    $CRMD
    SEC Filings

    See more
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      5/7/25 5:04:09 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by CorMedix Inc.

      10-Q - CorMedix Inc. (0001410098) (Filer)

      5/6/25 8:32:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CorMedix Inc. (0001410098) (Filer)

      5/6/25 7:45:34 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Cormedix with a new price target

      Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00

      3/7/25 7:21:39 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care